Human Genome Sciences Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate Sale of Human Genome Sciences to GlaxoSmithKline plc

DALLAS--(BUSINESS WIRE)--

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Human Genome Sciences (“HGSI”) HGSI to GlaxoSmithKline plc for shareholders. Under the proposed transaction, HGSI shareholders will only receive $14.25 in cash for each share of HGSI stock owned, well below the 52 week high of $23.84.

If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at patrick@powerstaylor.com, or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you.

The transaction is valued at approximately $3 billion.

The investigation centers on whether HGSI shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues HGSI stock, and whether HGSI's board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. According to at least one analyst with Yahoo! Finance, the true inherent value of HGSI may be as high as $23.00, well above the proposed transaction price. “Due to the lack of a significant premium to the shareholders and other factors, we believe that the transaction may undervalue HGSI stock. Our lawsuit will seek to obtain the highest share price for all shareholders,” said shareholder rights attorney Willie Briscoe.

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.